Armistice Capital’s Vivos Therapeutics VVOS Stock Holding History

Armistice Capital’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,115,859	Closed	-$1.32M	–	418
2026 Q1	$1.32M	Buy	+1,115,859	New	+$1.79M	0.02%	162
2024 Q2	–	Sell	-103,582	Closed	-$500K	–	386
2024 Q1	$500K	Buy	103,582 +46,582	+82%	+$278K	0.01%	201
2023 Q4	$709K	Buy	+57,000	New	+$489K	0.01%	187

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Armistice Capital's VVOS Position: Q2 2026 in Review

Armistice Capital sold out of Vivos Therapeutics (VVOS) in Q2 2026, closing a stake of 1,115,859 shares — an estimated $1.32M sold.

Armistice Capital first reported a position in VVOS in Q4 2023 and held it in 3 quarters. The position peaked at $1.32M in Q1 2026. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Armistice Capital reported no remaining Vivos Therapeutics position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 1,115,859 Vivos Therapeutics shares in Q2 2026, an estimated $1.32M.
Armistice Capital first reported a position in Vivos Therapeutics in Q4 2023 and held it in 3 quarters.
Armistice Capital's Vivos Therapeutics position peaked at $1.32M in Q1 2026.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.